Unknown Manufacturer
Vayarin is a prescription medical food for the clinical dietary management of certain lipid imbalances blamed to be associated with attention deficit hyperactivity disorder (ADHD) in children. Vayarin contains Lipirinen, a proprietary composition containing phosphatidylserine-omega 3, EPA (eicosapentaenoic acid), and docosahexaenoic acid (DHA) . Vayarin is currently available only by prescription in the USA . This drug has also been used for management of hypertriglyceridemia . Vayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. Vayarin is a specially formulated and designed to address the distinct, previously determined lipid nutritional requirements of children with ADHD, the dietary management of which cannot be achieved with lifestyle modification . Vayarin is a novel therapy for ADHD that appears to be effective in several studies . Approximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. Cost of the drug and patient aversion to the taste of Vayarin were significant reasons for therapy failure .
Vayarin is a prescription medical food for the clinical dietary management of certain lipid imbalances blamed to be associated with attention deficit hyperactivity disorder (ADHD) in children. Vayarin contains Lipirinen, a proprietary composition containing phosphatidylserine-omega 3, EPA (eicosapentaenoic acid), and docosahexaenoic acid (DHA) . Vayarin is currently available only by prescription in the USA . This drug has also been used for management of hypertriglyceridemia . Vayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. Vayarin is a specially formulated and designed to address the distinct, previously determined lipid nutritional requirements of children with ADHD, the dietary management of which cannot be achieved with lifestyle modification . Vayarin is a novel therapy for ADHD that appears to be effective in several studies . Approximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. Cost of the drug and patient aversion to the taste of Vayarin were significant reasons for therapy failure .
Phosphatidylserine (PS) in the mammalian nervous system, containing high levels of omega-3 fatty acids, has been implicated in numerous membrane-associated functions, such as maintaining the integrity of cell membranes, cell excitability and cell-to-cell recognition and communication. While the exact mechanism by which this medical food exerts its effects is not fully understood, PS has been found to regulate important proteins in neuronal cell membranes, including sodium/calcium ATPase and protein kinase C, which perform crucial functions in many signal transduction pathways. Similarly, PS interacts with Raf-1 protein kinase to promote a cascade of reactions that are believed to be involved in the survival of cells . Additionally, PS has been found to influence neurotransmitter activity, such as the release of acetylcholine (Ach), dopamine, and noradrenaline. In addition, it is also thought to increase brain glucose concentrations . Administration of specially processed formulations consisting of PS conjugated to omega-3 fatty acids was found to significantly increase DHA levels in the brain tissue of rats .
ADHD in children, hypertriglyceridemia .
